Wednesday, January 22, 2025 The MYC2 trial (SWOG S1803) - A Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study) - has closed Step #1 registration of new study participants having successfully reach the target accrual goal (n=1420 for Screening Step). Step #2 and Step #3 remain open.
